T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP

BACKGROUND: The study of individual negative symptoms is encouraged as they may have separate neurobiological substrates and require specific therapeutic strategies. Blunted affect is a decrease in the observed expression of emotion and may be more fluctuant than expected. We aim to investigate early trajectories of blunted affect in first episode schizophrenia (FES) patients without previous antipsychotic-treatment. METHODS: We included 82 first episode psychosis antipsychotic naïve patients meeting the DSM-IV criteria for schizophrenia, schizoaffective or schizophreniform disorder. All participant started risperidone (1-4mg) after the first assessment. Socioeconomic and demographic data were collected at baseline. Positive and Negative Syndrome Scale (PANSS) was applied at both assessments. PANSS negative component item N1 was used to access blunted affect. Participants were divided into three groups for each assessment according to their N1 score: (i) absence of symptoms - score 1 or 2; (ii) Mild intensity - score 3 or 4; and (iii) Severe intensity - score 5 to 7. RESULTS: Mean age was 25.77 (sd: ±7.27) years-old and 61% were male. Mean total PANSS was 92.74 (sd: ± 22.37) at baseline and 65.54 (sd: ± 20.42) at follow up. Mean risperidone dose at follow up was 3.71 (± 1.51). Forty three (52%) study participants had persistence of blunted affect at 10-week follow up regardless of symptom intensity. Sixteen (19.5%) patients never displayed blunted affect. In fact, the most common trajectories include participants who persists with the same symptom severity (n=48). Symptoms improved in 17 participants and got worse in 17 as well. Only one participant started the study without symptom and evolved to high intensity at follow up, while no participant started the study with high severity symptoms and evolved to absence of symptoms. DISCUSSION: Our study suggests that blunted affect exhibit different trajectories, but its intensity tends to remain stable over short-term follow up. Blunted affect may be unresponsive to risperidone at the beginning of treatment. Most of the previous studies addressed trajectories of negative symptoms as a group. Only few addressed the progression of blunted affect and, to the best of our knowledge, this is the first to use a sample of drug-naïve FES patients. Also, we selected only participants in use of risperidone after first assessment in order to reduce bias. A sample of drug naïve FES patients brings opportunities like assessing the course of blunted affect at an early phase of the condition and reducing confounders such as chronicity and exposure to antipsychotics.